false 0001896212 0001896212 2025-01-13 2025-01-13 0001896212 CDT:CommonStock0.0001ParValuePerShareMember 2025-01-13 2025-01-13 0001896212 CDT:RedeemableWarrantsEachWholeWarrantExercisableForOneShareOfCommonStockAtExercisePriceOf11.50Member 2025-01-13 2025-01-13 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): January 13, 2025

 

Conduit Pharmaceuticals Inc.

(Exact name of registrant as specified in its charter)

 

Delaware   001-41245   87-3272543
(State or other jurisdiction
of incorporation)		   (Commission
File Number)		   (I.R.S. Employer
Identification No.)

 

4851 Tamiami Trail North, Suite 200

Naples, FL

   34103
(Address of principal executive offices)   (Zip Code)

 

Registrant’s telephone number, including area code: (646) 491-9132

 

Not Applicable

(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the Registrant under any of the following provisions (see General Instruction A.2. below):

 

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
   
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
   
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
   
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   Name of each exchange on which registered
Common Stock, $0.0001 par value per share   CDT   The Nasdaq Stock Market LLC
Redeemable Warrants, each whole warrant exercisable for one share of Common Stock at an exercise price of $11.50   CDTTW   The Nasdaq Stock Market LLC

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company ☒

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

 
 

 

Item 5.07. Submission of Matters to a Vote of Security Holders.

 

On January 9, 2025, Conduit Pharmaceuticals Inc. (the “Company”), convened a special meeting of stockholders (the “Special Meeting”). The Company adjourned the meeting until 10:00 a.m. Eastern Time on January 13, 2025.

 

The Company reconvened the Special Meeting on January 13, 2025. Proxies had been submitted by stockholders representing over one-third of the shares of the Company’s common stock outstanding and entitled to vote, which constituted a quorum. At the Special Meeting, the Company’s stockholders voted on three proposals, each of which is described in more detail in the proxy statement.

 

The following is a brief description of each matter voted upon and the results, including the number of votes cast for and against each matter and, if applicable, the number of abstentions and broker non-votes with respect to each matter. Proxies for the Special Meeting were solicited pursuant to Section 14(a) of the Securities Exchange Act of 1934, as amended, and there was no solicitation in opposition of management’s solicitation.

 

Proposal No. 1. Stockholders approved the issuance of up to an aggregate of 2,862,596 shares of the Company’s common stock issuable upon the exercise of certain warrants to purchase the Company’s common stock, in accordance with Nasdaq Listing Rule 5635(d). The voting results were as follows:

 

Votes For  Votes Against  Abstentions  Broker Non-Votes
38,067,839  1,540,659  368,985  0

 

Proposal No. 2. Stockholders approved the issuance of up to an aggregate of 75,000,000 shares of the Company’s common stock issuable upon the conversion of the Senior Secured Promissory Note, as amended, entered into by the Company and Nirland Limited on August 6, 2024, in accordance with Nasdaq Listing Rule 5635(d). The voting results were as follows:

 

Votes For  Votes Against  Abstentions  Broker Non-Votes
35,000,998  4,608,682  367,802  0

 

Proposal No. 3. Stockholders approved the issuance of up to an aggregate of 58,000,000 shares of the Company’s common stock issuable upon the conversion of the convertible promissory note entered into by the Company and A.G.P./Alliance Global Partners on November 25, 2024, in accordance with Nasdaq Listing Rule 5635(d). The voting results were as follows:

 

Votes For  Votes Against  Abstentions  Broker Non-Votes
35,013,951  4,596,139  367,392  0

 

 
 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Date: January 14, 2025 CONDUIT PHARMACEUTICALS INC.
     
  By: /s/ David Tapolczay
  Name: David Tapolczay
  Title: Chief Executive Officer

 

 

v3.24.4
Cover
Jan. 13, 2025
Document Type 8-K
Amendment Flag false
Document Period End Date Jan. 13, 2025
Entity File Number 001-41245
Entity Registrant Name Conduit Pharmaceuticals Inc.
Entity Central Index Key 0001896212
Entity Tax Identification Number 87-3272543
Entity Incorporation, State or Country Code DE
Entity Address, Address Line One 4851 Tamiami Trail North
Entity Address, Address Line Two Suite 200
Entity Address, City or Town Naples
Entity Address, State or Province FL
Entity Address, Postal Zip Code 34103
City Area Code (646)
Local Phone Number 491-9132
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Entity Emerging Growth Company true
Elected Not To Use the Extended Transition Period false
Common Stock, $0.0001 par value per share  
Title of 12(b) Security Common Stock, $0.0001 par value per share
Trading Symbol CDT
Security Exchange Name NASDAQ
Redeemable Warrants, each whole warrant exercisable for one share of Common Stock at an exercise price of $11.50  
Title of 12(b) Security Redeemable Warrants, each whole warrant exercisable for one share of Common Stock at an exercise price of $11.50
Trading Symbol CDTTW
Security Exchange Name NASDAQ
Grafico Azioni Conduit Pharmaceuticals (NASDAQ:CDTTW)
Storico
Da Gen 2025 a Feb 2025 Clicca qui per i Grafici di Conduit Pharmaceuticals
Grafico Azioni Conduit Pharmaceuticals (NASDAQ:CDTTW)
Storico
Da Feb 2024 a Feb 2025 Clicca qui per i Grafici di Conduit Pharmaceuticals